Drug profile · INN
erenumab-aooe
AIMOVIG
erenumab-aooe (AIMOVIG) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — erenumab-aooe
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
erenumab-aooe (AIMOVIG) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Calcitonin gene-related peptide type 1 receptor antagonist
Primary target: Calcitonin gene-related peptide type 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is erenumab-aooe?
erenumab-aooe (AIMOVIG) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for erenumab-aooe?
AIMOVIG is a marketed brand name for erenumab-aooe. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of erenumab-aooe?
erenumab-aooe has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.